FOXO Technologies Inc. announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO's machine learning models to analyze epigenetic biomarkers; (ii) the Company's expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources. In connection with the new offering, the Company also announced it has formed a collaboration with KR8.ai Inc. ("KR8") and secured an exclusive license to KR8's AI-based software to support the development and commercial launch of the new health and wellness offering.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.268 USD | 0.00% |
|
+0.04% | -16.95% |
1st Jan change | Capi. | |
---|---|---|
-16.95% | 3M | |
-13.90% | 190B | |
+2.92% | 171B | |
+5.45% | 157B | |
+2.43% | 97.12B | |
+50.88% | 94.25B | |
+17.01% | 86.07B | |
+1.55% | 78.08B | |
-0.44% | 47.21B | |
-32.13% | 44.84B |
- Stock Market
- Equities
- FOXO Stock
- News FOXO Technologies Inc.
- FOXO Technologies Inc. Unveils Plans for New Direct-To Consumer Offering Combining the Company's Epigenetic Data with the Power of Ai